These uniform imaging plans are recommended despite the fact that women with germline BRCA2 mutations typically develop average prognosis estrogen receptor‐positive (ER+) breast cancer and women with BRCA1 mutations most frequently develop biologically aggressive triple‐negative breast cancers (TNBC) (Ha et al., 2017; Joosse, 2012). This evidence concerns the gene ESR1 and breast cancer.